MTNB - Earnings call transcript Q3 2021 | Matinas BioPharma Holdings, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings and welcome to Matinas BioPharma's Third Quarter 2021 Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Peter Vozzo, Investor Relations representative for Matinas BioPharma. begin. may you you, Thank

Peter Vozzo

with Thank Matinas you, joining conference thank for section. is press everyone Earlier business along updates. The website Good Matinas BioPharma under morning, release release a the issued results on morning, and financial third results this with the you available we Doug. our BioPharma quarter call. Investors XXXX the

Chief Dr. Scientific be Terry call on will Jerry Dr. DeBoer, Raphael Executive and today's Mannino, Chief Matkovits, Officer; Officer. Development Officer; Speaking Chief

have questions also Chief this projections statements of uncertainties. Officer Q&A hopes, We during to Terry Dr. Medical These made call involve future. Officer risks the At and remarks like this and Ferguson, intentions, Financial beliefs, Chief may remind expectations, available Keith that Management's forward-looking our time, session. during or Kucinski, I would to listeners answer our state

call Forward-looking and provisions laws. federal securities Harbor statements pursuant Matinas on current Safe statements on this to differ the materially. of results based may Biopharma's forward-looking are These made are actual expectations

you should on forward-looking reliance any not undue place result, statements. a As

to These Company's website Investors could the website. posted the documents factors call website, are SEC's section Commission. differ the Some available are also reports, in materially files in Company's such forward-looking cause contemplated on Exchange the that actual statements discussed results section. and this Investors of be periodic the will the BioPharma of Matinas from the Securities the and An those of with in to archive by

the call question-and-answer open call Jerry. a turn I we session. will will remarks, prepared to now Company's the the Following over for

Jerome Jabbour

today quarter we time thank and and a financial review business to everyone our morning, join for you Good third Peter. taking you, provide update. results XXXX the as us Thank

in and the third MATXXXX the data EnACT from safety half efficacy September, was Matinas announced trial of In with of quarter patients cryptococcal our first For we meningitis. transformational. XXXX of

from use while threshold two, supporting in on safety endpoint the demonstrating an impressive to of time MATXXXX and into six MATXXXX overall great the data weeks Bower, second exceeding Dr. performed optimism continue EnACT primary at we up half and that call, investigator. These David incredibly trial. longer the eliciting impressively of considerable oral outlined the profile impressive provide as term cohort same a the enthusiasm deal are As of the principal

the use extension FDA learning upcoming game become potentially the program important highly EnACT the treatment as more following external chose because commercially products her this successful our morning. Dr. and of Matkovits oral formulation can cohorts in treatment not part changing goal intentionally MATXXXX only X to oral could platform LNC including and combined into increased technology in of of consolidation, limit B. as and invasive Our our significantly. infections from to will and one LNC of indications meeting the an this for a prevention IV cryptococcal eventual our for part of in use detail all also amphotericin vulnerable infusion to for amphotericin be potential patients when and step include as the about amphotericin the We of the describe on MATXXXX for our most is disease. contained to for induction those immuno-compromised to options that position treatment quarter, label but demonstrate AmBisome regimen X altogether meningitis. both our IV similar remarks therapy could Thus fungal of to down in even for need extended and and an more transformational invasive prevention of with fungal in additional of significantly the potential treatment eliminate potentially other go past announcement, have word MATXXXX the utilized This interest

becoming now as platform are true recognized company. a We

now shift our potentially we believe exciting progress we LNC Our has in validated delivery. become are the programs platform a of world intracellular increasingly with that EnACT and focus to in player the positioned in important to broader been major

beyond second oral initiated to significant as pipeline, ascending our drug we MATXXXX amikacin, MATXXXX, broad-spectrum progress now LNC whole of our study X continue stage asset. to Phase including having a a advancing with dose Matinas Looking antibiotic the single recently formulation LNC aminoglycoside our clinical

class which of For completely MATXXXX the oral of this first to use develop is the could drugs. aminoglycoside our goal transform important

studies dosed with As preclinical healthy Phase positive dose study mentioned, Fibrosis year from PK in on earlier volunteers we this in recently X Cystic following collaboration the single FDA a we feedback conducted have ongoing ascending received Foundation.

acute and the oral infections. inhaled be warning. bacterial high deliver to use inhaled could enrollment therapies, available and continues therapy, its We the infections directly in the from to and and virtually and physicians. amikacin market, potentially Phase without MATXXXX's lung important could the Street study We unlike and in high distinguishes world narrow to of capture toxicity, by despite a to the for solution clearly product a levels XXXX. and patients used valuation like MATXXXX treat oral to an label other variety safe all Wall like NTM orally In have Insmed boxed very expect limiting it second of would quarter data MATXXXX broad-spectrum an quarter garner provide the a of ARIKAYCE, amikacin XXXX entire available that aminoglycoside of be X gram-negative first in complete believe to of ability positioned

clinic, we amount the As we MATXXXX this value increasing in attention to expect an of and continue from creation progress program.

drug promising to with forward companies. In pharmaceutical with continue leading advancing collaborations own addition we candidates, our our moving make progress platform to LNC our

the on and we conducted of efficient, end delivery efficacy of from antiviral about important North well remdesivir vivo before in more prodrug in Institute for commenced quarterly of use from a our the with antiviral University predictive would as Sciences, of this for an discuss of anticipate well-established this shared project class. model preclinical study LNC data effective, a of in will Carolina. demonstration update LNC safe but Gilead later, being National across Mannino study example, our Infectious last therapy cooperation platform call, with For the Dr. the Diseases year. and highly bode collaboration to and bit at We an has the of the extremely Matinas this Allergy

Finally, number like this a that Development for conducting over interest Based positioning I and would expressed the will the product MATXXXX call candidates, Terry potential remain to now who process the partnership I turn due potential at therapy. LYPDISO, of will process Dr. we clinical discuss the and diligence, companies and quarter our omega-X mention XXXX our a of two we in Matkovits, date, on will still our global to the minimum. of that licensing Chief believe best-in-class prescription of progress extend into Officer, first stage MATXXXX. engaged to

Terry Matkovits

Thanks Jerry and good morning everyone.

we significant MATXXXX, progress. oral made product, For our have amphotericin

during we have data two patients. this cohort that last schedule on trial. announced enrolled positive fully we ahead are we and the As of the our have of Jerry call, I'm cohorts X, moved EnACT the mentioned of XX morning from cohort we as earlier, happy report to of where first Since then to

view to we Before I'd in regulatory to briefly picture strategy of expect X, MATXXXX. see the our I of bigger the outline walk overall for like what you through specifics cohort

indications As MATXXXX. for you'll for working filing we are recall, towards NDA three an

treatment a with are cryptococcal of First, pursuing for days therapy an as two Flucytosine be down just amphotericin. treatment induction as we the to of meningitis used step IV indication following

product. the would for Second, of represent pursuing of total indication for indication treatment. any up This weeks we meningitis are for novel cryptococcal a B for currently use first amphotericin six consolidation treatment a available to long-term

relevant any we all treatment. and administered package overall with intravenous Third and their amphotericin the official feedback B meningitis oral treatment This cryptococcal share will for potential X, is FDA especially registration month for next indication with for an next for cohorts the to X for need meningitis eliminating potentially plan year. early be and induction cryptococcal discussed Flucytosine an

fungal severe streamlined Importantly, safe bridge we agency and a for for and Disease for registration Breakthrough XXX infections such cryptococcal mucormycosis caused a those prophylaxis oral as down, [indiscernible], meningitis additional is follow-on for and/or name aspergillosis treatment the MATXXXX the by only severe treatment of Orphan believe of package. specifically meningitis, deadly the development pathway pathway the of around to to and we a discussions and in meningitis step infections as initial and consolidation, opportunity recognition treatment effective are and allow invasive Leveraging with represents preparing that fungal with additional designations, to other invasive us the of with data streamlined beginning. designation few. (b)(X) induction for the clinical other gateway the cryptococcal The potential indications, potential a cryptococcal MATXXXX will as

MATXXXX recall all regiment may test five active with on and of to that the critical are given X time patients, the treatment fungal of as and in of of during specifics Patients efficacy first five clearance. treatment to oral Now assess impact on includes first days of MATXXXX treatment. potential oral starts leading the to in cryptococcal and turning X X initial control, our for is X potential monitored cohort induction with the are MATXXXX in during a you EnACT, of a XX Cohort treatment XX total meningitis. a pilot cohort for back MATXXXX initial test combination which these of Flucytosine the carefully days

with MATXXXX, patients for are days to Following remainder Flucytosine induction amphotericin, through of of the administered the Phase five day with switched initial the again treatment XX. IV

Phase again During MATXXXX six. fluconazole receive treatment continue the with to cohort patients consolidation week in X through

for cohort decisions that be the that on well. of would review are formal the end the enrolled, enrollment in cohort and fully pleased that that cohort Based full We the convene of and DSMB of the reported year. schedule, data X now the patients is completion, will expect we ahead and doing enrollment progression very are is before current the a to

six consolidation evaluation. induction X be X the to be of would DSMB cohort by our progression, of in things with plan phases commencement cohort its to enrollment decision X. of as cohort and DSMB are that the and the we hope As part of the see the announce and are considered There from that to likely

in a no initial counts of within of activity the First, MATXXXX MATXXXX. reduction treatment fungal with days five fungal antifungal in indicating growth first potent increase

of trial. activity end critical the above the fungicidal for than endpoint X.X, primary this of induction early the greater at Second, threshold

rates the published in historical phases greater Next, consolidation continuing induction XX%. of replicating than MATXXXX patients fungi during of or is which the XX-week therapy, absence Achieving receive of all treatment. to survival early sterility either

of cohort progression signal kidney X that and attributable overall MATXXXX would each evidence for announcement the treatment toxicity breakthrough recurrent without MATXXXX profile DSMB no has achieved. approved infection to of positive strong have been Next, to these a that safety during or finally, An be MATXXXX. an objectives

to pleased progress. am now with we Turning I to share oral our nanocrystal to make amikacin lipid continued strong also you MATXXXX, that formulation, have

As is last formulation. we conducted we oral are patient ascending in dosed first and an This dose expected XXXX. of results U.S. announced half month, being single in the study clinical the amikacin trial our of first optimized a in

toxicology we necessary Importantly, of the ongoing July. in continuing parallel FDA studies, the clinical meeting conduct which are with in was to to studies, our focus

of And We Additional longer-term on of you longer update longer indications support these turn All over remdesivir. our to update for Mannino favourable programs the pursue I'll Dr extended to infection, inflammation. eradication profile therapy. clinical extend hold an of MATXXXX. of long-term date Raphael with for and toxicology that requires clinical continuing leveraging or our studies other progress require in platform LNC treatment forward early MATXXXX who to for in to will for active safety courses of and platform of will infection the other durations us data treatment the the studies ongoing to the studies XX targeted also the MATXXXX Having program, the call to for may potentially the on continued look available hope to provide toxicology the delivery can development that, for drugs term MATXXXX which and support longer. are of X to months planned future of completed XXXX flexibility even NTM MATXXXX this of infections Phase providing you since our be site with with work planned

Raphael Mannino

everyone. morning, good and Terry, you, Thank

have of delivery formulation to proprietary utilizing we Matinas, previously, Institutes bioavailable of and orally LNC program an Health Gilead ongoing an research As National the collaborative platform remdesivir. our announced develop have

preclinical in and to the both the lung studies update bioavailable levels Before antimicrobials status B, of has infections has infections. that tissue both delivered when amikacin, penetration MATXXXX our I'd to LNC development treatment of some number studies. of to compared briefly Oral background of over models project, MATXXXX orally collaboration. in rapid studies of demonstrated in MATXXXX, of therapy. effective and this and this to PK of oral led programs The lung efficacy included the entire proved a course severe in the providing on preclinical pre-clinical for exciting orally Candida an that bioavailable of like that demonstrated formulated demonstrated work candidiasis amphotericin review the our parentally MATXXXX up and mouse be very more treatment Aspergillus PD controlled drug systemic amphotericin the more

and and is complete addition, platforms, LNC specific a models models of studies infection, and and has when orally at parameters a delivery process MATXXXX the to drug ability nanoparticle It administered amphotericin new formulations that and of least B. this of LNC each with essence, Similarly, excipients flexibility customize looking in in allows in cystic delivery it of around lung systemic model involving encapsulation provided evaluated in where or demonstrated In be oral of infection studies biofilm parental buffers unlike MATXXXX creating the eradication even enhanced used. the is used efficacy in ratio, can manufacturing systemic significant settings other the at unique of setting infections be mouse as non-tuberculosis as and customize optimize these concentrations almost PH. properties controlled, well salt lipid as for to better number of mouse specific all as related remember a preclinical to to as compared slightly it such solvents, design treatment important aspergillosis chemical been than in survival MATXXXX that formulation physical the to molecule In to the delivered that mycobacterial formulation unique an going infections we good further amikacin. was parental disseminated In fibrosis. mouse to

culture unlike We efficacious when demonstrate oral correlation proof tends disconnect strong subsequent between also results have evaluating that cell-based a efficacy in-vivo that cell noted models a formulations studies. are formulations areas that large there of where LNC and animal in there antimicrobials, in in-vitro be therapeutic other can be concept results and between the to in

we Having this on Now, we the candidates next LNC have back that different coming the oral moved several to of formulations stage testing. models of promising have through program, now NIH reported LNC in-vivo contract the oral in-vitro previously number a remdesivir remdesivir have system. identified evaluated work, we to based in in-vitro

the drug. effective addition intracellular and another this In the pulmonary previous to a of to of namely specific prodrug remdesivir, oral support treat the enzymes is our form study processed must important remdesivir fact antiviral delivery strong with to infections. and is by With work that consideration be in is there CNS rapid order active antimicrobials that potentially

bioavailable While, to an delivery this orally improved optimistic is continue provide and of LNC formulation formulation how our intracellular a it prodrug, about the first of capabilities our we LNC platform be of could very remdesivir.

preclinical the is year. of anticipate before end ongoing and remdesivir LNC in-vivo the having new initial we results Our study

and Following we results. Gilead, buy discussions to in would approval, necessary receiving concerning NIH with their an and make the these hope announcement and

and inside of for intracellular would anti-viral can results model first cells, the While than small antiviral success. confirm option that, inside spectrum is cells. intracellular now expanded serious which delivery only The both and implications have of their safe more should there the can an infection. animal with and replicate the a and compounds, remdesivir, the formulation of unique non-immunogenic molecules. broad a delivery antifungals, even is replicate potential entire additional agents. potential utility mechanisms antivirals. of of number viral targeting for could remdesivir ideal by of positive Unlike first with important a drugs for ultimate of implications fungi oligonucleotides, formulation are the LNC and beyond profile clinical make variety Work Positive to LNC the of results delivery Accordingly, molecules simple that and just platform work small are nontoxic wide anti-infectives, across intracellular use complex and step. to delivery implications antibiotics LNC viruses in-vivo for essential antiviral But as of well-established LNC broader including cell positive outside there the delivery inhibiting of data a in replication, an efficient bacteria, viral

expect and discuss some will the polymers acid We complex lot to even results RNA be financial back learn and now from thoughts. study a this and oligonucleotides able messenger and to over like more apply including antivirals, at to provide then I to potentially UNC areas, Jerry, will learnings turn who final our potentially call other gene therapy. nucleic these

Jerome Jabbour

To with marketable in of able in to on of operations XX, approximately of the sufficient XX, XXXX expenses need, two financial same in LNC summarize now results; XXXX. life we our progress valuable with securities how quarter have Raphael. at current To net and pose the and million a $X.X share platform shareholders LNC markets, were a both XXXX significant same Research in our quarter administrative the areas per The and our and third targeted $X.X $X.X platform our period to December or common domestically globally. believe medical million, approximately were solution at to and become $XX.X approximately compared been human XXXX. fund during shareholders basic million we is million a expenses that for on Infectious to of and and projections, XXXX. share, $X.X pleased address I to conclude of briefly in of large were and General to development, $X.XX in products compared XXXX, company $XX.X million to candidates Based significant to or clinical loss product we prepared to diluted XXXX. both disease approximately unchanged equivalents basic $X.X cash, Thanks believe cash development the continues am potential continue cash hand into in in million million attributable a same per net to $X.X quarter period of loss compared approximately third for essentially a XXXX. net and compared September threat extremely the patients. XXXX. loss to have reported $X.XX attributable And the remarks, that diluted we million can common

of year, a expect evaluation we the DSMB head progression would drug As we this potential be MATXXXX, for toward that good great that end our induction and has therapy. for oral which assessment sign very

are a looking forward to therapy. our step potential MATXXXX also approval December FDA and evaluate in pathway to data meeting available for discuss all a with We early down

delivery partners year, major could can look commands LNC from yield study end continue and of a that We vehicle, with completing with technology the in space. player X a XXXX. data of our The $X.X data promising, advance a at expected first antiviral variety in currently be our and vivo this ongoing single of further can provide to announcing to forward and is our with MATXXXX to efficacy profile plus become cap. evidence alternative Gilead drug and market of efficient, We a the NIH that we the which to much billion half by of our today for a enrollment drug the promise safe as remdesivir our looks better effective LNC extremely in of intracellular a to delivery be Phase and molecules. dose differentiated MATXXXX believe study Ultimately, ascending the technology holds potentially an

administration opportunities complex solve enormous by its progress. to we and to delivery what is and a RNA. session. oral back acid will and as I the future LNC We messenger believe for the unique to is presented our vaccines intracellular on our such to call believe to potential turn question-and-answer and of look to polymers over continue our operator challenges nucleic the ability We forward continuing extremely evaluate capitalize we the you that, bright, platform, on update With

Operator

Securities. from the Please Instructions] [Operator question with proceed your Mayank first line Our Mamtani you. with comes of B. Thank question. Riley

Unidentified Analyst

is questions. taking [ph] Thank This for Juan on for team. you Hi, Mayank. our

efficacy, started? development Thank a So potentially we'll the you viral NIH dive-in plan think the possibility could here. the and the What's LNC for remdesivir drug improve can that so that formulation there's you. the Do reduce load? it UNC after the

Jerome Jabbour

vivo thank about people one efficacy a because much curious of and with our your steps to remdesivir LNC the of of it's a become and believe very positioned Hi, are NIH and what beyond attention question a given that we and lie advancement you for antivirals program in good member study to very the Gilead we're oral meaningful recently development has been and and group. lot this

order what then X in have wait study to in unique intracellularly. see of upon Phase these data efficient to based into knowledge to a get ability works plan We our this molecules like study, how manner to the delivered looked go our and an exact our aggressively from in technology vivo to

Remdesivir terms we efficacy our that be could in demonstrated have course, upon we seen doing other dependent. improve of clinical that, are What upon to at a in have the that's but data terms profile similar improving them sites antimicrobials that already to significantly safety of drug. ability efficacy, in time, there's Of in of believe the deliver our delivering of by improve we a ability possibility and platform seen going we infection, to and the trials, in LNC the encapsulating we fashion them same to

to and are important at generated this important from data been the program. be And very, these very human into see always then to depending that is NIH we in that move are. expect has wait driver of data, have expectation into our for very aggressively of on So the we to what Matinas the very, the Gilead, the forward UNC those but we data XXXX, studies evaluation would clinic, very a

Unidentified Analyst

given of addition to on the helpful LNC for in the challenges lung you another hear And would is, like the your Thank the would oral question delivery you, direct color. to to thoughts delivery, and think, to example, molecule for like possible it in I be the lung LNC the vectors delivery small what Thank you. will other deliver via -- formulation? your viral with with [indiscernible] remdesivir field

Jerome Jabbour

Dr. for you I'll the question address Thank to Sure. Mannino one. this ask and

Raphael Mannino

Yes, question. for thank you the

We One to and including to of in drying drying. layers LNC to formulations dies mice, stable, them no already by been There's then of fluorescent deliver make short, only make aspect only was the up have is touch is suspensions, also mouse, able to including by it able out cells. inhalation, dry lung spray things within also bed of we fluid are but in upon water this. within but models. not another LNC other inside that the of molecules, That technology to allows anhydrous. but the very us taken material which didn't in the today, positive just are lyophilization, see types not make of powders, were and LNC And but dog coming we the give

intranasally, in about infection. a we in able this influenza a were with when in to therapeutic. LNCs to three down XXX-fold model viral considered siRNA study dose of an addition, the delivered model load days later by able mouse siRNA were -- And do is we tenfold single In knock

lung have to directly deliver compatible is suggesting into So data ability the technology. LNC the we with that do early the

Unidentified Analyst

Thank you. Thank we you. have. That’s all

Operator

your Hazlett question. Please next the Our line question proceed BTIG. from Bert with with of comes

Robert Hazlett

remdesivir of a just the development Thank just, Gilead in you the for as relationship bigger picture the one, two relationship got well. question. congratulations the general then you this Thank and maybe studies? characterize I've Is with Can specific taking at you and point. again characterization the Jerry and Gilead contemplated one progress. there further some on ones or

Jerome Jabbour

Yes. Thanks, Bert.

could by relationship we of to then groups directly with And brought flexibility NIH. and essentially the to driven the in much we it understanding a a down that in XXXX, collaboration sort what could on enter two as the brought to symbiotic scientific preserve we table. determined demonstrate is way. a our that really wanted they our focusing deepened until together of to over course value. technology were tie thought remdesivir was to we NIH, and that with really technology when of into able as of this They So the continue benefit relationship this not better And terms

As precedent a technology, need to we you on about careful value. platform be early an setting advance do

goal was vivo into work to could, And in hands get so as it. our get and remdesivir as studies in with our on and these quickly we vitro the

the know As cement conversations this progressed vivo impressive it of to important then will very with the this, to be able And our early we in of in and data, because us have the particularly we've data nature but of Gilead aspect a are. for vitro where take really advanced. that's and

through in delivery model proof-of-concept So right flexibility. you we this now, drug why of intracellular very antivirals. I of one this a a the reasons is fight the as would about remdesivir characterize potentially lens, the our It's well-established against important in relationship COVID-XX. of Matinas relationship the about one view of course, as But if look at

drug want ends by the great directions model proof-of-concept it for Gilead, flexibility in with go to preserved one number more this that cement up preserve is a paid benefit then in being of our our we could of a sort different But gives promise to and flexibility us like we a our than the which have our of to the with vivo those antivirals. of own So relationship in direction another If either that's a go clinically delivery remdesivir. antiviral, or of NIH on remdesivir, thing. even investigate

flexibility. as it characterize would I So

Robert Hazlett

for color. Thanks additional the

study? this to to a be program, the is out specifics, XXXX a with registrational progression regard or mapped do of to And and there point? you two one potential and Phase have Phase for X, Just X at kind that program

Jerome Jabbour

that, things at ask I'll the Sure. Dr. may I to Matkovits some on and add end. comment

Terry Matkovits

Yes. the Thanks Bert. for question,

as to MATXXXX, opportunity us two with the unique regulatory that streamline to allow MATXXXX we has the believe leverage program. would development So pathways

pathway second we of of the for XXX(b)(X) is is approved current The the as of and ARIKAYCE and is is regimen the efficacy registration can as rely part the treatment streamlining indication. the for as amikacin orphan and infections that's contribute for Since believe that NTM will the the treatment treatment been first NTM, with the well amikacin upon orphan development products will that to demonstrated data with we the IV already pathway.

that treatment all profile expect we continue streamlined allow we'll as that bring work done assumption has so to fashion clean see be So able to they FDA this of course, drug. with to And a a the is us with to safety in MATXXXX, our of to this patients. will

Robert Hazlett

with you with in to with Okay. X made need And interact interaction just comments the you guess, give I hand FDA, as think, some to mentioned a agency? just that would to cohort what Thank your you just one for then regard believe you really I X with you cohort picture would have positive in regard to XXXX, what big a you additional as strong clarify, really color. And Could just question. in then drive, you comments, you earlier. see I

Terry Matkovits

So we our as allow have step-down the meaningful have believe a us drug agency for the will data to that we therapy. already very a with discussion

in already endpoint. have believe that we data. the So We've seen the the with patients primary step-down survival exceeded We've we excellent therapy.

for available be FDA for already will X cohorts the data So our based that's focus on and X. engagement

that to without that's of to cohorts. want mortality. cohorts, package that continue continued X.X outcome be to a and that indication. survival to in culture with EFA X And X sterilization as toxicity. will seen no course, those And tied first and see exceeds evidence importantly, to data in from have X the been of ensure cohort any induction that we renal treatment safety all-oral of of patients improvements X, first want see We'll want We'll to clinical relapse. the very shows excellent or rebound the strong with threshold support as For data we the the the we'll see

Robert Hazlett

that that. you structurally, I clarity. thank the other in picture Terrific, additional Jerry, in kind characterize it's you about then goal or in think how your think here, opening potential in terms, in you are with the industry. is industry? kind there And think for is of other things a development terms think Gilead and something in NIH. players XXXX comments, alluded that know or can with achieved the interactions you just be the recognition we've with industry? on efforts, of of you mentioned are that to you company to partnerships, other you where Again, players in technology this difficult And do like just we've mentioned But partnerships, of I those do big interactions as do that -- general

Jerome Jabbour

course, again Bert, good and come It's a there's mention to relationship year it we continue for actively immunogenicity, with. unwanted no lot by that on the inbound especially or discussions to call, highlighted real We've toxicity, areas We're interest that of a highlighted to inefficiency intracellular RNA, of act. It's as of a technology. us, for of Gilead lot. that anyone by side. today there's balancing Yes. one engaged But challenges, a there like extended shouldn't those a delivery specific gene who we be didn't And for like -- in surprise interest medicine, and obviously, of and sorts therapy, we others. our of Genentech, the another continue delivery messenger get in work question, and to delivery, to following on EnACT, of lot it's innovative were like We a example, things the in these there delivery that. either asked

in We have Matinas. XX employees

timeliness those We of are ongoing. collaboration further like be to able to to this validate lot discussions continue We projects. a have and ongoing would to areas, a in one with technology those those. There's a of

goal that for happen goal characterize XXXX. beyond of before broaden something robust beyond absolutely would may those XXXX, a molecules, is use It discussions antivirals. of so small as this a I the ongoing. and is to technology the And further And company

the the So we ways of this at but we utilization one are looking focused increasing that intently is of destiny. own on controlling our technology, remain this

are would our a because and XXXX drugs, XXXX be than us, be and advancing those are can So we can what commercialized customary own destiny, effort two other commercialization then those approved that and with through drugs for for control drugs. less key hopefully

about everyone, ours. organization a in like it's to we to to we partners be relationship choose would you say want of we're overwhelm can So careful but a management engage with here. the have then lot flexibility small I because say collaborations great

around of sense it a our urgency a drive discussions in makes areas, have to sense which key So a continue we're point they're to and concentrating finalize where at until we few we'll those. those

Robert Hazlett

Congrats and to the look I progress. the Thank far, so additional you forward for forward again to color. look on it more. Thanks.

Peter Vozzo

Thanks, Bert.

Operator

next Our with line the Greg comes of your questions. question from Fraser Truist. with proceed Please

Greg Fraser

the about abscessus? program, effective like, with population, from patients initial It how I'm think oral MAC with questions. MATXXXX, but be yes, but the I you're like who patient might target development Good morning, thinking obviously early both. those XXXX whether could sounds curious NTM, the know more the mycobacterium it's you that delivery also patients inhaled taking do On Thanks for current in it's benefit versus drug. for difficult-to-treat

Jerome Jabbour

I'll characterize of just the limited, comment as not and to efficacy I I demonstration briefly of the Yes. available be think, beginning. to we're -- therapy. poor Absolutely, significant Terry I'll the toxicity -- let would at going

for to So on We've preclinically. we've of one Foundation, MAC of also preclinically has there. after actually also Fibrosis attention drug. both worked all, of competitive cystic which our go the the get really can significant products inability first indication infections, But that Cystic the And shown to believe NIH the reasons where We is ability we drug put beyond with the to unlike go attention disseminated pulmonary NTM limited that's if drug have infections. for not effective right -- drug, an well and competitive this this on the the need a of just with patients impact we've that's up because an M-abscessus is attracted its that treatment unique because to treatment because which at nontoxic ability lung of would MAC. is the these to their in And to be way. fibrosis the set really be

here, think in with terms But we see to do would add to a a I Terry? going indication laddered beyond far what data But there, and anything XXXX. indication of initially, plan you're to so sort stacked going we look approach, the support similar to MAC. approach And of disease, NTM

Terry Matkovits

the compelling exactly data The at cystic in in model, of Foundation. University that by really fibrosis the Dr. has Jerry's No, Fibrosis seen the we Colorado are Cystic that data mouse to we've are remarkable from the data receiving preclinical generated Diane Yes. Ordway. very, compelling, been very support point,

So oral potentially able we're the we platform [ph] this have safety how how Daly product now treated with can where an clinical Dr. and and utilizes profile that benefit strong do of and to oral see preclinical validation our we from that program. the outpatient we can advisor with is, experts they experts even leverage key our at be of as to setting is leverage who see amikacin our in on product. our we the that field, can look patients What including an monotherapy in such

the looking validation how experts preclinical we So and leverage these NTM for us, can we that been potentially the better regimens look with how at unique and patients. this clinical with optimize to important, has safety the we've current critically efficacy treating at for intend to coupled preclinical to profile monotherapy see convene we seen, treatment the

as seen mapping the program, be we strong can, but clinical we broad to safety we're we've are that the So to date. looking as in of out leveraging phases the early

Jerome Jabbour

actually, like and approach we we inquiry, would outline what had Foundation, benefits access to is approached a and expertise of us patient get patients. Cystic benefit they the the as that group of And Cystic of one Fibrosis we of an with the to sort X you look the submit their Fibrosis responded and to And as Phase of Foundation working like. experience advocacy

of program as studies, collaborating long of like. tox months So one treatment as all of been even longer. reasons long-term outlining these because Phase course and NTM we're It's be XX can already X for on the why look sort what would conducting of we've a the

as of that why goal established, And XXXX. lot the program be advocacy can with a that's studies during patient we so the of a and the Foundation so unmet are also can is as support our to streamlined of sort put we together groups significant Cystic to continues Phase address X comprehensive what need. into of development But we've but a Fibrosis KOLs lineup entering we other these and

Greg Fraser

the Great. Thanks all on color congrats the progress. for and

Jerome Jabbour

Thanks, Greg.

Operator

I'd There to Mr. closing to are the like hand for in no remarks. further the back questions queue. call Jabbour

Jerome Jabbour

and our Thank interest day. looks thank team your us and a to for joining appreciate progress. you, today. Have updates our We entire you forward future providing continued with on here in Matinas, all Doug, great you

Operator

Thank you participation. Ladies and your gentlemen, this for teleconference. does conclude today's

at your wonderful and day. disconnect this may You time, a lines have

Matinas BioPharma (MTNB) 8 Nov 212021 Q3 Earnings call transcript